Overview

Clinical Trial Comparing BL123 Versus Ketoconazole in Patients With Tinea Pedis

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
This is a non-inferiority, Phase II, open-label, randomized, parallel trial to evaluate efficacy and safety of the new intervention (Dapaconazole cream 2%) versus the active control (Ketoconazole cream 2%) in patients with Tinea Pedis. Study schedule comprises enrollment, treatment and follow-up visits. Treatment period is 14 days.
Phase:
Phase 2
Details
Lead Sponsor:
Gilberto De Nucci
Collaborator:
Biolab Sanus Farmaceutica
Treatments:
Ketoconazole